Boston Scientific (BSX)
(Delayed Data from NYSE)
$73.17 USD
-0.09 (-0.12%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $73.13 -0.04 (-0.05%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$73.17 USD
-0.09 (-0.12%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $73.13 -0.04 (-0.05%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth A Momentum B VGM
Zacks News
Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).
Compared to Estimates, Boston Scientific (BSX) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Boston Scientific (BSX) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Boston Scientific (BSX) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Boston Scientific (BSX) delivered earnings and revenue surprises of 4.17% and 1.77%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
NextGen (NXGN) Q2 Earnings Top Estimates, Margins Down
by Zacks Equity Research
NextGen's (NXGN) second-quarter fiscal 2024 results reflect strength in its Recurring revenues.
Medical Device Stocks' Q3 Earnings Due on Oct 26: BSX, BIO & More
by Urmimala Biswas
Medical Device companies' third-quarter results are likely to reflect a year-over-year decline. Let's see how BSX, BIO, EW and LH fare this time.
Shockwave Medical (SWAV) Announces IVL Studies' Positive Results
by Zacks Equity Research
Shockwave Medical's (SWAV) latest announcement of two new publications validates the utility of IVL in complex nodular and eccentric calcium.
What's in Store for Boston Scientific (BSX) in Q3 Earnings?
by Zacks Equity Research
With global staffing issues and the supply situation gradually improving, Boston Scientific's (BSX) international business is expected to have improved further in the third quarter.
The Zacks Analyst Blog Highlights Visa, AbbVie, BHP Group, Caterpillar and Boston Scientific
by Zacks Equity Research
Visa, AbbVie, BHP Group, Caterpillar and Boston Scientific are included in this Analyst Blog.
Top Research Reports for Visa, AbbVie & BHP
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), AbbVie Inc. (ABBV) and BHP Group Limited (BHP).
Boston Scientific's (BSX) Wavewriter Alpha SCS Gets FDA's Nod
by Zacks Equity Research
Boston Scientific (BSX) receives the FDA's nod for an expanded indication of Wavewriter SCS Systems.
QuidelOrtho (QDEL) Reports Solid Preliminary Q3 Revenues
by Zacks Equity Research
QuidelOrtho's (QDEL) revenue growth in the third quarter is likely to have been boosted by continued strength in its non-respiratory product sales.
Walgreens Boots (WBA) Q4 Earnings Miss Estimates, Margins Down
by Zacks Equity Research
Walgreens Boots (WBA) Q4 retail revenues are impacted by macroeconomic-driven consumer pressure and lower COVID-19 OTC test kit sales.
Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Boston Scientific (BSX) and Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) have performed compared to their sector so far this year.
5 Medical Product Stocks to Buy Amid Industry Recovery
by Indrajit Bandyopadhyay
Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. SYK, BSX, ZBH, PODD and HAE are well-poised to gain from the favorable factors.
Neogen's (NEOG) Q1 Earnings Miss Estimates, Margins Rise
by Zacks Equity Research
Neogen's (NEOG) Q1 Animal Safety business experiences continued destocking, with channel inventory levels reaching multi-year lows.
Here's Why You Should Invest in Boston Scientific (BSX) Now
by Zacks Equity Research
Investors are optimistic about Boston Scientific (BSX) on consistent growth and upbeat guidance.
AngioDynamics (ANGO) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
AngioDynamics (ANGO) registers strong revenue growth in the Med Tech business in first-quarter fiscal 2024.
PBH or BSX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PBH vs. BSX: Which Stock Is the Better Value Option?
Exact Sciences (EXAS) Aided by Innovation, Strategic Buyouts
by Zacks Equity Research
Exact Sciences (EXAS) is planning several key milestones to bring six innovative cancer diagnostics from its pipeline to patients in need.
Is Boston Scientific (BSX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Boston Scientific (BSX) and Conmed (CNMD) have performed compared to their sector so far this year.
The Zacks Analyst Blog Highlights Amazon.com, Boeing, Regeneron, Boston Scientific and Waste Management
by Zacks Equity Research
Amazon.com, Boeing, Regeneron, Boston Scientific and Waste Management are part of the Zacks top Analyst Blog.
Boston Scientific (BSX) Set to Acquire Relievant Medsystems
by Zacks Equity Research
Boston Scientific's (BSX) new M&A deal is likely to broaden the Neuromodulation business portfolio.
Top Stock Reports for Amazon.com, Boeing, Regeneron & Others
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), The Boeing Company (BA) and Regeneron Pharmaceuticals, Inc. (REGN).
PBH vs. BSX: Which Stock Is the Better Value Option?
by Zacks Equity Research
PBH vs. BSX: Which Stock Is the Better Value Option?
Boston Scientific (BSX) WATCHMAN FLX Pro Gets FDA Approval
by Zacks Equity Research
Boston Scientific's (BSX) latest device features a polymer coating, visualization markers and a broader size matrix to treat a wider range of patients.
Here's Why You Should Retain Boston Scientific (BSX) Now
by Zacks Equity Research
Investors are optimistic about Boston Scientific (BSX) on growth in the legacy business and upbeat guidance.